Gilder Gagnon Howe & CO LLC Phathom Pharmaceuticals, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

$7.87 Billion
Q3 2024

A detailed history of Gilder Gagnon Howe & CO LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 1,622,883 shares of PHAT stock, worth $14.2 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

1,622,883

Previous 1,472,259 10.23%

Holding current value

$14.2 Million

Previous $15.2 Million 93.49%

% of portfolio

0.37%

Previous 0.2%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $1.54 Million - $2.94 Million	150,624 Added 10.23%	1,622,883 $29.3 Million
Q2 2024 Aug 14, 2024	BUY	$8.97 - $12.05 $4.08 Million - $5.48 Million	454,642 Added 44.68%	1,472,259 $15.2 Million
Q1 2024 May 15, 2024	SELL	$6.21 - $11.05 $2.72 Million - $4.83 Million	-437,515 Reduced 30.07%	1,017,617 $10.8 Million
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $1.01 Million - $1.55 Million	145,084 Added 11.07%	1,455,132 $13.3 Million
Q3 2023 Nov 14, 2023	BUY	$10.26 - $15.7 $2.56 Million - $3.92 Million	249,443 Added 23.52%	1,310,048 $13.6 Million
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $3.69 Million - $7.26 Million	506,776 Added 91.5%	1,060,605 $15.2 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $12,392 - $24,744	2,002 Added 0.36%	553,829 $3.95 Million
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $5,645 - $7,090	-615 Reduced 0.11%	551,827 $6.19 Million
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $23,662 - $44,358	-3,663 Reduced 0.66%	552,442 $6.12 Million
Q2 2022 Aug 15, 2022	SELL	$6.2 - $15.5 $1,165 - $2,914	-188 Reduced 0.03%	556,105 $4.69 Million
Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $118,248 - $205,374	10,238 Added 1.87%	556,293 $7.57 Million
Q4 2021 Feb 14, 2022	SELL	$17.83 - $33.15 $74,618 - $138,732	-4,185 Reduced 0.76%	546,055 $10.7 Million
Q3 2021 Nov 15, 2021	BUY	$30.69 - $36.83 $114,105 - $136,933	3,718 Added 0.68%	550,240 $17.7 Million
Q2 2021 Aug 16, 2021	SELL	$32.66 - $39.87 $8.88 Million - $10.8 Million	-271,863 Reduced 33.22%	546,522 $18.5 Million
Q1 2021 May 17, 2021	BUY	$33.86 - $48.68 $27.7 Million - $39.8 Million	818,385 New	818,385 $30.7 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $344M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.

Account

Gilder Gagnon Howe & CO LLC Phathom Pharmaceuticals, Inc. Transaction History